“The first thing I noticed wasn’t the weight loss. It was that I stopped wanting to buy things,” says Dr. Sarah Chen, a behavioral economist at the London School of Economics who has been tracking consumer spending patterns since mid-2023. “And that’s when I knew we were looking at something bigger than just a pharmaceutical story.”
She’s right. The explosion of GLP-1 receptor agonists — drugs like Ozempic, Wegovy, and Mounjaro — isn’t just reshaping waistlines. It’s quietly reshaping the entire consumer economy, from what people put in their shopping carts to how they spend their disposable income. And the data is starting to tell a story that has Wall Street paying attention.
A recent analysis by the BBC examined spending patterns among users of these weight-loss medications, and the results are striking. Users report feeling less hungry — not just for food, but for the whole cycle of consumption that drives modern retail. The impulse buy at the checkout. The mid-afternoon snack run. The emotional shopping spree. It’s all taking a hit.
Look at the numbers. A survey of 2,000 GLP-1 users in the UK and US conducted by market research firm Numerator found that food spending dropped by an average of 11% within the first three months of use. But here’s the kicker — spending on non-food items also fell by 6%. That includes categories like cosmetics, skincare, and even mouthwash and hair dye.
Why mouthwash? Because the drugs can cause a metallic taste in the mouth, and users often ditch products associated with that sensation. Hair dye? Some users report changes in hair texture or reduced interest in grooming routines. It sounds trivial, but in aggregate, these shifts represent billions in potential revenue losses for consumer goods giants.
The dopamine disconnect
To understand this, you have to understand how GLP-1s work on the brain. These drugs mimic a hormone that signals fullness, but they also cross the blood-brain barrier and reduce the reward response to food. And it turns out, that reward system isn’t just for cheeseburgers.
“We’re seeing a dampening effect on what economists call ‘hedonic consumption’ — purchases driven by pleasure rather than necessity,” explains James Whitfield, a retail analyst at Bernstein. “It’s not that people stop buying entirely. But the emotional charge of shopping diminishes. The dopamine hit isn’t there anymore.”
This is a big deal for companies that rely on impulse purchases. Think about the candy bars at the register, the scented candles near the entrance, the $5 lip gloss that catches your eye. Those micro-decisions add up to billions annually. If a significant chunk of the population becomes less susceptible to them, the math changes.
And the population using these drugs is already significant — and growing. According to the BBC, prescriptions for GLP-1s in England alone doubled between 2023 and 2024, with over 1.5 million people now using them. In the US, that number is estimated at 15 million and climbing. That’s a consumer segment large enough to move market needles.
What goes down, what goes up
Not all categories are suffering. Some are actually benefiting from the shift. As users eat less, they tend to seek out higher-quality, nutrient-dense foods. Sales of protein shakes, vegetables, and meal-prep services are up. But the bigger winners might be in unexpected places.
“We’re seeing a rotation into experiences rather than goods,” says Maria Torres, a consumer behavior researcher at the University of Cambridge. “People report feeling more in control, more focused. They’re spending on travel, fitness classes, even home renovations. The money isn’t disappearing — it’s moving.”
That aligns with broader trends. Travel bookings among GLP-1 users are up 8% year-over-year, according to a survey by Morgan Stanley. Gym memberships and personal training sessions are also climbing. The drugs seem to unlock a kind of behavioral discipline that spills over into other areas of life.
But there’s a darker side. Some users report reduced interest in social activities that revolve around food or drink — dinners out, cocktail hours, even coffee dates. That could hurt restaurants and bars, particularly in the mid-range segment. Fine dining might survive because it’s about more than just eating, but the casual chain restaurant? That’s a different story.
For a real-world example of how shifting consumer behavior can ripple through the economy, consider the 1 million UK homeowners facing a £45 monthly mortgage hike in two years. As household budgets tighten, any change in spending patterns — whether from drugs or debt — gets magnified. The two stories are more connected than they seem.
The retail reckoning
So what does this mean for investors? Start with the consumer staples sector. Companies like Nestlé, Unilever, and Procter & Gamble have already started mentioning GLP-1s in their earnings calls. Nestlé has launched a line of protein-rich frozen meals specifically targeting users of weight-loss drugs. That’s a direct admission that the old playbook is under threat.
“The market is pricing in a 10-15% haircut on snack food valuations over the next three years,” says Whitfield. “That might be conservative. If adoption rates continue to accelerate, we could see a structural shift in demand that lasts a generation.”
Think about that. A drug originally developed for diabetes could end up reshaping the global food industry. It’s not unprecedented — the rise of health consciousness in the 1980s killed the tobacco-sponsored sports era and launched the low-fat craze. But this is faster, more direct, and more pharmacological.
Meanwhile, the beauty and personal care sector is watching warily. Sales of makeup and skincare products dipped 4% among GLP-1 users in the latest quarter, according to NielsenIQ data. The reason isn’t entirely clear — it could be the metallic taste effect, or it could be that users feel less need to compensate with external enhancements when they’re happier with their bodies. Either way, it’s a red flag for companies like L’Oréal and Estée Lauder.
And then there’s the alcohol industry. Early data suggests GLP-1 users are drinking less — not because of any directive, but because the desire for alcohol’s dopamine hit also diminishes. That’s bad news for brewers and distillers, who are already struggling with declining consumption among younger demographics.
But let’s not get ahead of ourselves. The drugs are expensive — around £200-£300 per month in the UK without insurance, and $1,000+ in the US. That limits the addressable market to those who can afford it or have coverage. And side effects — nausea, vomiting, potential thyroid tumors — mean not everyone sticks with them. Dropout rates in clinical trials are around 15-20%.
Still, the direction is clear. As generic versions emerge and prices fall, adoption will widen. The Samsung profits skyrocketing 1,800% as AI chip demand booms shows how quickly a technological shift can reshape an industry. The GLP-1 revolution might be slower, but it’s just as profound for consumer behavior.
The bottom line
For the average consumer — and the average investor — this is a reminder that markets are never static. The things we take for granted about spending habits are contingent on biology, psychology, and regulation. A pill that changes how you feel about food changes how you feel about everything.
“We’re only at the beginning of understanding these effects,” says Dr. Chen. “If this class of drugs becomes as widespread as statins or antidepressants, the implications for consumer economics are enormous. We’re talking about a potential recalibration of demand across multiple sectors.”
So keep an eye on your portfolio. If you’re heavy on snack stocks, it might be time to rotate. And if you’re a retailer, you’d better start figuring out how to sell to a customer who isn’t hungry — for anything.
The next time you reach for that mouthwash at the pharmacy, ask yourself: would you still buy it if you didn’t really want it? Millions of people are about to find out.
Frequently Asked Questions
How quickly do GLP-1 drugs change spending habits?
Most users report noticeable changes within 2-4 weeks of starting the medication. The effects on impulse purchasing are often reported alongside appetite suppression, suggesting a neurological link between food cravings and other forms of consumption.
Which industries are most at risk from this trend?
The snack food industry is the most directly exposed, with potential revenue declines of 10-15% forecast. Alcohol, fast food, and impulse-buy categories like cosmetics and confectionery are also vulnerable. Conversely, fitness, travel, and premium food sectors may benefit as spending shifts.
Will these effects last if people stop taking the drugs?
Early evidence suggests that changes in behavior are largely dependent on continued use. When patients stop taking GLP-1s, appetite and reward-seeking tendencies typically return within weeks. However, if users maintain new habits formed during treatment, some behavioral changes may persist.
